Panobinostat and Multiple Myeloma in 2018

Panobinostat and Multiple Myeloma in 2018

FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2018-05, Vol.23 (5), p.516-517
Hauptverfasser: Yee, Andrew J., Raje, Noopur S.
Format: Artikel
Sprache:eng
Schlagworte:
Commentaries
History, 21st Century
Humans
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Panobinostat - pharmacology
Panobinostat - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2017-0644